Join the RAPS Twin Cities Chapter for an engaging and practical session focused on understanding clinical study design and statistics as they apply to medical device regulatory strategy. This session ...

A major international trial suggests that a widely available antidepressant may help ease one of long COVID’s most disabling symptoms, bringing patients and clinicians closer to a practical treatment ...

1. FDA Reminds More Than 2,200 Sponsors and Researchers to Disclose Trial Results. News release. FDA. April 13, 2026.

Fluvoxamine, a common and affordable antidepressant, significantly reduces persistent fatigue and debilitating lethargic symptoms while improving the quality of life for long COVID patients. Fatigue ...

Rare disease is a major – and growing – area of clinical research and drug development. Of the FDA’s 46 novel drug approvals in 2025, more than half (26) were designated as rare disease (orphan) ...

The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients ...

India, April 7 -- Fluvoxamine, a common and affordable antidepressant, significantly reduces persistent fatigue and debilitating lethargic symptoms while improving the quality of life for long COVID ...

PhaseV, a leader in AI/ML for clinical development, today announced its "Mt. Emerson" level sponsorship and participation in the Timmerman Traverse - a multi-day expedition across the Evolution Range ...

SEED-SET enhances ethical evaluation of autonomous systems through a hierarchical Bayesian framework, optimizing alignment ...

Prediction error refers to the mismatch between an expected outcome and the actual outcome. When a prediction error occurs, the brain updates its ...

A new systematic review published in Brain, Behavior, and Immunity suggests that using cannabinoids does not have a single, ...